Genome Editing Market Update: Intellia Therapeutics Presents Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy

Intellia Therapeutics logo

Intellia Therapeutics, one of the leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology is presenting one oral presentation and four poster presentations at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) meeting taking place October 22-25, 2019, in Barcelona, Spain. The global genome editing market is anticipated to grow at a CAGR of 12.6% during the forecast period 2023-2035.

Get a complete list of the presentations, here.

How is the genome editing market landscape evolving: Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on CRISPR technology.  Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated.

Infographic: Evolution of Genome Editing

Why is CRISPR gaining so much traction:  Over the years, more than 10,000 patents related to the CRISPR technology have been filed/granted to various industry players and academic institutions, indicative of the ongoing pace of R&D in this field of research. The immense benefits offered by CRISPR makes it one of the most preferred genome editing approach.

Infographic: Why is CRISPR gaining

Elaborate profiles of the prominent genome editing companies (shortlisted based on a proprietary criterion) developing genome editing technologies. Each profile features a brief overview of the company, details related to its financial information, technology portfolio, recent developments and an informed future outlook. Further, the chapter also includes profiles of other leading players developing genome editing technologies. 

Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of gene editing technique (CRISPR-Cas System, TALENs, meganucleases, ZFNs and other techniques), type of therapy (cell therapies, gene therapies and other therapies), gene editing approach (gene knock-out approaches and gene knock-in approaches), gene delivery method (ex-vivo and in-vivo), gene delivery modality (viral vectors and non-viral vectors), application area (drug discovery and development, and diagnostics), type of end user (pharmaceutical and biotechnology companies, and academic and research institutes)

To get more insights about the genome editing market, check out the report

One Comment